COVID-19 and Clinical Trials

The CRI Anna-Maria Kellen Clinical Accelerator published our first analysis on the impact of COVID-19 on oncology clinical trials in May 2020. We recently performed a one-year review of the impact that is now available to the larger scientific community. Our aim is to inform the cancer research community of challenges, risks, and contingencies through these updated analyses and publications.

Clinical Trials Stopped Due to COVID-19

In order to continue monitoring the pandemic, we compiled all clinical trials stopped due to COVID-19 below using


COVID-19 and Clinical Trials

While some clinical trials have reported stopping due to COVID-19, more have emerged to treat patients with COVID-19. We have compiled all clinical trials from where COVID-19 was mentioned as the condition for enrollment.


Timeline of non-PD-1/PD-L1 Immuno-Oncology Agent Approvals by the FDA

Clinical Trial Analysis Publications

Data Sources: Cancer Research Institute (CRI) analytics derive from public data sources, including trade news, company press releases, academic publications, FDA announcements,, and conference reports, and proprietary data sources including, but not limited to, GlobalData. The analytical algorithm and visualizations are developed by and therefore sole property of Cancer Research Institute.

Subscribe to our email newsletter to receive the latest updates on our landscape analyses.

Do you want more information on the Clinical Accelerator? Contact us

IO Landscapes

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.